¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"T cell antigen receptors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î¼º
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷, Á߽ɼ±¹æ¼¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷, ģũ·Ò¼¼Æ÷
  • chromophilic cell
    »ö¼Òµê¼¼Æ÷, È£»ö¼Ò¼¼Æ÷
  • chromophobic cell
    »ö¼Ò¾Èµê¼¼Æ÷
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • dust cell
    ¸ÕÁö¼¼Æ÷
  • delayed cell-mediated reaction
    Áö¿¬¼¼Æ÷¸Å°³¹ÝÀÀ
  • delta cell
    µ¨Å¸¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • chromaffin cell
    ģũ·Ò¼¼Æ÷, Å©·Òģȭ¼¼Æ÷
  • chromophilic cell
    »ö¼Òµë¼¼Æ÷, È£»ö¼Ò¼¼Æ÷
  • chromophobic cell
    »ö¼Ò¾Èµë¼¼Æ÷
  • ciliated cell
    ¼¶¸ð¼¼Æ÷, ÀÜÅм¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • clear cell hidradenoma
    Åõ¸í¼¼Æ÷¶¡»ùÁ¾
  • clear cell sarcoma
    Åõ¸í¼¼Æ÷À°Á¾
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • columnar absorptive cell
    ±âµÕÈíÂø¼¼Æ÷
  • committed cell
    ¾ô¸Ç¼¼Æ÷, ¼öÀÓ¼¼Æ÷
  • complex cell
    º¹ÇÕ¼¼Æ÷
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • antigen,fetal
    žƼº(÷Ãä®àõ)
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • antigen,heyman
    ÇìÀ̸¸
  • antigen,histocompatibility
    Á¶Á÷ÀûÇÕ¼º(ðÚòÄîêùêàõ)
  • antigen,hla- d
    HLA-D
  • antigen,oncofetal
    Á¾¾çžƼº(ðþåË÷Ãä®àõ)
  • antigen,sequestered
    °Ý¸®(̰×î)
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • antigen-antibody complex
    Ç׿ø-Ç×üº¹ÇÕü
  • antigen-antibody complex, soluble
    ¼ö¿ë¼º Ç׿ø-Ç×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿ø-Ç×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿ø-Ç×ü¹ÝÀÀ
  • antithetical antigen
    »ó¹Ý(ßÓÚã)¼º Ç׿ø
  • functional antigen
    ±â´É(Àû) Ç׿ø.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • functional antigen
    ±â´É(Àû) Ç׿ø.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen (HBc Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen (HBs Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • hepatitis B surface antigen(HBs Ag)
    BÇü °£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    ÀÌÁ¾Ç׿ø.
  • heterologous antigen
    ÀÌÁ¾Ç׿ø
  • heterophil(e) antigen
    ÀÌÁ¾Ä£È­(¼º) Ç׿ø(¡­ù÷ê«).
  • heyman antigen
    ÇÏÀ̸¸ Ç׿ø, Heyman Ç׿ø
  • hidden antigen
    ÀºµÐÇ׿ø, ÀºÆóÇ׿ø
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕÇ׿ø
  • histocompatibility antigen, major
    ÁÖÁ¶Á÷ÀûÇÕÇ׿ø
  • hla-d antigen
    HLA-D Ç׿ø
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • Epitheloid muscle cell
    »óÇǼº±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǾç±Ù¼¼Æ÷
  • Chromophilic cell
    »ö¼Òµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÈ£¼º¼¼Æ÷
  • Pigment cell
    »ö¼Ò¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò¼¼Æ÷
  • Chromophobic cell
    »ö¼Ò¾Èµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÇø¼º¼¼Æ÷
  • Cell inclusions
    ¼¼Æ÷Æ÷ÇÔ¹°
    [¿¾ ¿ë¾î] ¼¼Æ÷Æ÷ÇÔ¹°
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½ÉÀåÀÚ±ØÀüµµ¼¼Æ÷
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ǫ¸£Å²¿¹¼¼Æ÷
  • Exocrine cell
    ¿ÜºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜºÐºñ¼¼Æ÷
  • Villous muscle cell
    À¶¸ð±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] À¶¸ð±Ù¼¼Æ÷
  • Chief cell
    À¸¶ä¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Milk secreting cell
    Á¥ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] À¯¼¼Æ÷
  • Purkinje cell
    Á¶·Õ¹Ú¼¼Æ÷
    [¿¾ ¿ë¾î] Purkinje¼¼Æ÷
  • Ovoid cell
    Ÿ¿ø¼¼Æ÷
    [¿¾ ¿ë¾î] ³­¿øÇü¼¼Æ÷
  • Oxyphilic cell
    È£»ê¼º¼¼Æ÷
    [¿¾ ¿ë¾î] »êÈ£¼º¼¼Æ÷
  • Lutein cell
    Ȳ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] Ȳü¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
TSSA tumor-specific cell surface antigen
VCSA viral cell surface antigen
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
NK cell Natural Killer cell
RS cell Reed Sternberg cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
NK cell natural killer cell
P-cell Purkinje cell
TCRBCL T cell rich B cell lymphoma
B cell cell
G cell gastrin cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • direct cell division
    Á÷Á¢ ¼¼Æ÷ ºÐ¿­
  • disintegrated cell
    ºØ±« ¼¼Æ÷
  • dorsal horn cell
    Èİ¢ ¼¼Æ÷, ¹è°¢ ¼¼Æ÷
  • dorsal horn pain transmission cell
    ¹è°¢ ÅëÁõ Àü´Þ ¼¼Æ÷, ¹è°¢ µ¿Åë Àü´Þ ¼¼Æ÷
  • ductal cell
    µµ°ü ¼¼Æ÷
  • ductule cell
    ¼Ò°ü ¼¼Æ÷
  • ealry squamous cell calcinoma
    ÃÊ±â ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ±¸°­ ³» °¡Àå ÈçÇÑ ¾Ç¼º ÁúȯÀ̰í Ä¡°úÀǻ簡 Ä¡·áÇÏ´Â ¸î ¾È µÇ´Â Ä¡¸íÀû ÁúȯÀÇ ÇϳªÀÌ´Ù. Çǰ³ »óÇÇ ¼¼Æ÷ÀÇ ¾Ç¼º ¾ÏÁ¾¼º Áõ½ÄÀÌ´Ù. ¹é¹ÝÁõÀ̶ó°í ÇÏ´Â ÀÓ»ó ¿ë¾î·Îµµ ºÒ¸®´Â ¼Ò»ó »óÇÇ ºñÈÄ¿Í µ¿ÀÏÇÑ º´¼Ò¸¦ º¸¿©ÁØ´Ù. °¡Àå ÈçÇÑ ¿øÀÎÀ¸·Î »ý°¢µÇ´Â °ÍÀº ½À°üÀûÀÎ Èí¿¬°ú ¾ËÄÝÀÌ´Ù. ±¸°­ Á¡¸·¿¡ ¼Ò»ó ¹é»ö ¹ÝÁ¡À» ¸¸µå´Âµ¥ ÀÌ´Â »ý¸®Àû °ú°¢È­¿Í ºñ½ÁÇÏ°Ô º¸ÀδÙ. º´¼Ò¸¦ °ÇÁ¶½ÃŲ ÈÄ ÀÚ¼¼È÷ °üÂûÇϸé ÀÌÇü¼º º´¼ÒÀÇ Ç¥¸éÀÌ ÀϹÝÀûÀ¸·Î ´õ °ÅÄ¥°í ÂÞ±ÛÂÞ±ÛÇÑ °ÍÀ» º¼ ¼ö ÀÖ´Ù.
  • educated T cell
    Ç׿øÀ¸·Î °¨ÀÛµÈ T ¼¼Æ÷
    In vivo ¶Ç´Â in vitro¿¡¼­ Ç׿ø ÀÚ±ØÀ» ¹Þ¾Æ ¸é¿ª ±âÀüÀ» ¹ßÇöÇÒ ¼ö ÀÖ´Â »óŰ¡ µÈ T ¼¼Æ÷ÀÌ´Ù. In vivo¿¡¼­´Â ÀϹÝÀûÀ¸·Î Ä¡»ç·®ÀÇ ¹æ»ç¼±À» Á¶»çÇÑ Áã¿¡ ´Ù¸¥ µ¿¹°·ÎºÎÅÍÀÇ Èä¼± ¼¼Æ÷¸¦ ÀÌÀÔÇÔ°ú µ¿½Ã¿¡ Ç׿øÀÚ±ØÀ» ÇÏ´Â ¹æ¹ýÀÌ »ç¿ëµÈ´Ù.
  • endosteal cell
    °ñ³» ¼¼Æ÷
    À§Ä¡¿¡ ÀÇÇØ º¯°æµÇ°í, È®ÀεǴ ¸Á»ó ¼¼Æ÷. °ñ ³»¸·Àº °ñ¼ö ±âÁúÀÌ ³óÃàµÈ »óÅ´Ù.
  • endothelial cell
    ³»ÇÇ ¼¼Æ÷
  • enkephalinergic cell
    ¿£ÄÉÆÈ¸°¼º ¼¼Æ÷
  • eosinophilic cell
    È£»ê±¸
  • epidermoid type cell
    À¯Ç¥ÇÇ ¼¼Æ÷
  • epithelioid cell
    »óÇÇ¾ç ¼¼Æ÷, À¯»óÇÇ ¼¼Æ÷
    °áÇÙ µîÀÇ À°¾Æ¼º ¿°Áõ Áúȯ¿¡ À־ À°¾Æ ¼Ó¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ´Â Á¶Á÷±¸ÀÇ È£Äª.
  • ethmoid cell
    »ç°ñ ¹úÁý, »ç°ñ ºÀ¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
receptors, calcitonin gene-related peptide Cell surface proteins that bind calcitonin gene-related peptide (cgrp) with high affinity and trigger intracellular changes which influence the behaviour of cells. Cgrp receptors are present in both the central nervous system and the periphery and are not the same as calcitonin receptors.
(12 Dec 1998)
receptors, calcitriol Proteins, usually found in the cytoplasm, that specifically bind calcitriol, migrate to the nucleus, and regulate transcription of specific segments of DNA. Vitamin d is converted in the liver and kidney to calcitriol and ultimately acts through these receptors.
(12 Dec 1998)
receptors, catecholamine Cell surface proteins that bind catecholamines with high affinity and trigger intracellular changes which influence the behaviour of cells. The catecholamine messengers epinephrine, norepinephrine, and dopamine are synthesised from tyrosine by a common biosynthetic pathway.
(12 Dec 1998)
receptors, ccr5 Seven-transmembrane G-protein-coupled receptors for beta-chemokines. They also function as fusion cofactors for macrophage-tropic HIV-1 strains.
(12 Dec 1998)
receptors, chemokine Cell surface glycoproteins that bind to chemokines and thus mediate the migration of pro-inflammatory molecules. The receptors are members of the seven-transmembrane G-protein-coupled receptor family.
(12 Dec 1998)
receptors, cholecystokinin Cell surface proteins that bind cholecystokinin (cck) with high affinity and trigger intracellular changes influencing the behaviour of cells. Cholecystokinin receptors are activated by gastrin as well as by cck-4, cck-8, and cck-33. Activation of these receptors evokes secretion of amylase by pancreatic acinar cells, acid and pepsin by stomach mucosal cells, and contraction of the pylorus and gall bladder. The role of the widespread cck receptors in the central nervous system is not well understood.
(12 Dec 1998)
receptors, cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behaviour of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.
(12 Dec 1998)
receptors, colony-stimulating factor Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells.
(12 Dec 1998)
receptors, complement Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement.
(12 Dec 1998)
receptors, complement 3b Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
(12 Dec 1998)
receptors, complement 3d Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor.
(12 Dec 1998)
receptors, concanavalin a Glycoprotein moieties on the surfaces of cell membranes that bind concanavalin a selectively; the number and location of the sites depends on the type and condition of the cell.
(12 Dec 1998)
receptors, corticotropin Cell surface receptors that bind corticotropin (acth, adrenocorticotropic hormone) with high affinity and trigger intracellular changes. Pharmacology suggests there may be multiple acth receptors. An acth receptor has been cloned and belongs to a subfamily of g-protein-coupled receptors. In addition to the adrenal cortex, acth receptors are found in the brain and immune systems.
(12 Dec 1998)
receptors, corticotropin-releasing hormone Cell surface proteins that bind corticotropin-releasing hormone with high affinity and trigger intracellular changes which influence the behaviour of cells. The corticotropin releasing-hormone receptors on anterior pituitary cells mediate the stimulation of corticotropin release by hypothalamic corticotropin releasing factor. The physiological consequence of activating corticotropin-releasing hormone receptors on central neurons is not well understood.
(12 Dec 1998)
receptors, cxcr4 Seven-transmembrane G-protein-coupled receptors for alpha-chemokines. They also function as fusion cofactors for T-cell-tropic HIV-1 strains.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á